YIDU TECH (02158.HK) traded at HKD 2.915 intraday on Oct 26, up 1.22%, down 23.1% since its removal from Stock Connect on Sept 7; FY2026 revenue rose 14.6%.
Hong Kong indices fell this week, with the HSI down 4.52% and the HSTECH down 5.76%, while southbound outflows reached HK$17.046 billion over four sessions.
On October 26, 2026, ALPHAMAB-B (09966.HK) announced that Phase I/II results of JSKN033 in cervical cancer after failure of standard treatment were presented at the 2026 ESMO Congress, with an ORR of 41.9% and a median PFS of 7.0 months.
HUA HONG GRACE (01347.HK) fell 4.45% to HKD 64.450; 8-inch wafer capacity will shrink 2.4% in 2026 as AI server power demand surges, and Q3 lands 5 November.
On October 26, 2026, ALPHAMAB-B (09966.HK) announced that Phase III results of Anbenitamab (KN026) in first-line HER2+ breast cancer and second-line or later HER2+ gastric cancer were presented at the 2026 ESMO Congress as LBA oral presentations.
On October 26, 2026, YIDU TECH (02158.HK) said its affiliate won the next-generation big data platform project of The First Affiliated Hospital of Chongqing Medical University, worth about RMB13.29 million.
EXELLAND ROBOT (03231.HK) fell 1.04% to HKD 34.400; Zhejiang service robot output rose 91.0% in Q1-Q3, and Agibot set a Guinness record with 110 robots.
Recent listings fell in the week to October 23, 2026: STAR GROUP ASIA gained 77.49%, MICOT PHARMA-B fell 39.92% and Z.AI led turnover at HK$3.838 billion.
On 26 Oct 2026, an HKEX notice said HAITONG UT's (01905.HK) H shares and two bonds (84497, 85014) resume trading at 9 am that day, with no reason given.
On 26 Oct 2026, HUTCHMED (00013.HK) said its SAFFRON trial met its PFS goal, with 7.6 vs 5.4 months (HR 0.55) in MET-driven EGFR-mutant NSCLC.
On 26 Oct 2026, GENFLEET-B (02595.HK) reported first-in-human GFH276 data at ESMO: ORR was 41.1% in 61 evaluable PDAC patients and 45.5% in 11 NSCLC patients.
On 26 Oct 2026, SBP GROUP (01177.HK) said TQB2102's Phase III APEX-Breast01 showed median PFS of 16.4 vs 5.5 months (HR 0.29) in HER2-low breast cancer.
On 26 Oct 2026, CARSGEN-B (02171.HK) said Phase Ib results of CT041 in gastric cancer were shown as an ESMO poster, without data being disclosed.
On 26 Oct 2026, ASCLETIS-B (01672.HK) filed an IND with the US FDA for ASC39, an oral amylin agonist for obesity, with Phase I expected in Q4 2026.
On 23 Oct 2026, EB ENVIRONMENT (00257.HK) said its consortium won a Dongguan waste-to-energy concession, with phase 1 investment of about RMB2.25bn.
On 23 Oct 2026, SINOPHARM (01099.HK) posted unaudited nine-month revenue of RMB427.61bn, down 0.89%; net profit RMB8.08bn and attributable profit RMB5.31bn.
